Fiscal 2026 Q3 Financial Results

AUGUST 2026

Legal Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading “FY 2026 Guidance”, statements regarding future growth and expansion including fiscal 27, estimated turnaround times, drivers of future revenue and gross margin growth including expected growth of AI-enabled discovery and projected serviceable market, market size and growth, estimated annual and fourth quarter fiscal 2026 revenues, ability and timing to achieve profitability, ability and timing to achieve adjusted EBITDA breakeven and ability to maintain or increase gross margins and Twist’s other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or noncompetitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated with the spin out of Atlas Data Storage; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K filed with the SEC on November 17, 2025. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

The presentation also contains supplemental financial information determined by methods other than in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP measure are not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. A reconciliation of these non-GAAP financial measures may be found starting on page 26 of this presentation.

A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company’s future hiring and retention needs, as well as the future fair market value of its common stock, all of which are difficult to predict and are subject to change. The actual amount of these expenses during fiscal 2026 will have a significant impact on Twist’s future GAAP financial results.

14 Consecutive Quarters of Sequential Revenue Growth



Serving Customers Across Multiple Industries

Therapeutics

Diagnostics

Academic
& Government

Industrial
& Applied

AI Driving Durable Growth in Short, Medium, Long Term

Large pharma

Traditional pharma

Dry lab biotech

Large tech companies

Biotech

Model Building

Generate the biological data for foundational model

Conducting Discovery using Models

(Turning the Crank)

Accelerate discovery through rapid design, build and test cycles

Model Iterating

Create recurring value through continuous model improvement (new modalities, etc.)

AI Aims to Reduce Future Costs, Improve Attrition and Shrink Timelines

Molecules that survive each stage of traditional drug discovery

Discovery & screening
5,000–10,000*
compounds screened

Preclinical
~250*
enter preclinical

Phase I
~5*
first-in-human

Phase II
~2*
advance to Phase III

Phase III & approval
1*
approved medicine

Cost at each stage

Once failures are carried, one launch costs ~$873M out-of-pocket, ~$1,778M capitalized§

Discovery & screening
~$3.5M§
per molecule
(target-to-hit, hit-to-lead)

Preclinical
~$15M§
per molecule
(lead optimization, preclinical)

Phase I
~$15M§
per molecule

Phase II
~$40M§
per molecule

Phase III & approval
~$190M§
per molecule
(Phase III, submission to launch)

* *Intuition Labs.ai.. § Paul et al., *Nat Rev Drug Discov* 2010: out-of-pocket cost per molecule by phase (Pharmaceutical Benchmarking Forum data); wedge heights indicative, not linear.

AI-Enabled Discovery: A Durable Growth Engine

TWIST BIOSCIENCE

1 Design
AI-Generated Sequences
Millions of candidate DNA sequences generated and refined in silico
Customer

2 Build
DNA Synthesis
High-throughput synthesis of increasingly complex individual genes and pooled DNA
Twist

3 Build
Protein Expression
Expression of the proteins encoded by the synthesized DNA
Twist

4 Test
Characterization
Assays predicting binding, developability and other critical features
Twist

5 Test
Lead Candidates
Highest-potential candidates advance toward preclinical development
Outcome of the cycle

Preclinical development & animal studies
Robust front-end iteration can save significant downstream cost
Downstream

Learn Assay data informs the next design round — each turn of the cycle drives repeat orders

Competitive Advantage

Complex DNA at scale · protein expression · high-quality characterization data · consistent results at the speed modern discovery requires

Triple-digit % growth for AI-enabled Drug Discovery

FY26 Order Growth vs. FY25

Guided at May Investor Day — three quarters in, we feel confident we will meet or exceed that target.

Expanding funnel

Breadth of Demand

Repeat programs, new customer acquisition, and new organizations forming or expanding into life sciences.

FY27 Triple-digit % growth for AI-enabled Drug Discovery

FY27 Visibility

Visibility to triple-digit percentage order growth for AI-enabled discovery in fiscal 2027 compared to fiscal 2026.

Supporting Global Health

Twist Comprehensive Viral Research Panel

- Over 1M unique probes
- Target 3,153 viral genomes
- Background:
  - May 15, 2026, public health officials in the Democratic Republic of Congo (DRC) announced developing outbreak of hemorrhagic fever.
  - Outbreak went undetected for at least a month, escaping standard PCR assays
  - Gap allowed virus to spread further
- One month later, researchers used Twist's Comprehensive Viral Panel to identify the pathogen as Bundibugyo Ebola virus, underscoring the value of whole viral genome enrichment to catch emerging infectious diseases

Rapid synthesis capabilities

- Rapidly synthesized hantavirus material in less than 24 hours to support response efforts during the cruise ship outbreak in May

Twist Comprehensive Viral Research Panel

Strong Accelerating Momentum for NGS Applications

Revenue growth led by diagnostic customers

Escalation of commercial volumes and pre-commercial activities

New opportunities

- Next generation assays
- Tumor-informed MRD tests
- Optimized workflows using proprietary enzymes

Inaugural Investor Day

Wilsonville, OR

Customer presentations across multiple markets and applications including:

- DSPS: enzyme engineering, siRNA drug discovery, AI-enabled discovery, academic research
- NGS: MRD, exome sequencing, FlexPrep for AgBio, OEM partnership

Scaling innovation with:

- Operational excellence, commercial execution, manufacturing discipline, digital capabilities

One Twist Team: culture drives success

Robust and Expanding Competitive Moat

- Manufacturing
- Automation
- Software
- Commercial Execution
- Product Development
- Customer Engagement
- Scientific Innovation
- Customer Experience

TWIST BIOSCIENCE

Existing Infrastructure Supports Continued Scale



Continuing to Iterate and Improve Proprietary Platform

- Continuing low error rate with improved **consistency**
- Continue to **reduce reagent cost** and **chemical waste**
- Faster synthesis **increases writer capacity,** enhances products, and expands throughput
- Enables **new product introductions**

All data is for ~1,000,000 oligos at femtomole scale

Cost
($)



~60%
reduction
in cost

Waste
(Liter)



~70%
reduction
In waste

TAT
(Hr)



~73%
reduction
in TAT

~4x
increase
in capacity

Complex DNA.
Simple everything else.

Complex gene synthesis from Twist

- ✓ Simple, automated ordering
- ✓ Complete transparency
- ✓ Predictable turnaround time
- ✓ Reliable synthesis
- ✓ Affordable pricing

During early access*:

>1,800	>100	12 day
complex genes	orders	turnaround time for majority of orders

*Early access data for the period April 15, 2026 to July 21, 2026

3Q FY26: On Track to Adj EBITDA Breakeven in 4Q FY26

$118.4M Revenue

Beat Guidance of **$114-115M**
Revenue Growth of **23% YoY**

52.8% Gross Margin

~120 basis points of sequential growth compared to 2Q FY26

$(11.3)M Adj. EBITDA*

Approaching breakeven

Cash, Cash Equivalents and Short-term Investments as of 06/30/26

$167 million

*See adjusted EBITDA reconciliation on page 28.

DNA Synthesis & Protein Solutions

3Q FY26

- $56.6 million in revenue
- Growth of 39% YoY and 6% sequentially
- Physically shipped approximately 369,000 genes
- Sequential growth for genes manufactured for data characterization

Next Up

- ✓ Custom library generation
- ✓ Libraries with yeast transfer
- ✓ Gene fragments in 2-4 days
- ✓ IgG characterization
- ✓ Expanded vectors
- ✓ Yeast display for antibody optimization
- ✓ Ultra complex genes
- ✓ Longer genes
- mRNA
- GMP
- Increased scale
- CHO expansion
- Additional channel partnerships
- High throughput bispecific Abs

TWIST BIOSCIENCE

Products

- Clonal genes
- Express genes
- Complex genes*
- Gene fragments
- MGF
- Characterization
- Oligo pools
- Gene Pools
- Variant libraries

Antibody services

- Discovery
- Developability
- Functionality
- Accessibility

*New or updated products/services

NGS Applications

3Q FY26

- $61.8 million in revenue
- Growth of 12% YoY and 8% sequentially
- Twist Comprehensive Viral Research Panel enabled researchers in the DRC to identify a rare strain of Ebola that evaded PCR tests

Next Up

- ✓ TrueAmp Library Prep kit
- ✓ PCR-Free WGS kit
- ✓ TrueAmp Polymerase
- ✓ cfDNA tools for alternative sequencers
- ✓ V2 methylation detection system
- ✓ Oncology CGP panel

- MRD Express
- Oncology CGP RNA
- Additional WGS enablement
- Additional long read tools
- Additional library prep enzymes
- High mass ssDNA

TWIST BIOSCIENCE

Products

- Fixed panels
- Custom panels
- Alliance panels
- Library prep kits
- Reagents
- Controls and standards

Services

- Pre and post-sale application support
- Bioinformatics
- Automation
- Service Lab*
- Pilot Lab

*New or updated products/services

Revenue by Geography



3QFY26 Industry Revenue Reporting

Industry Reporting (% change vs. 3QFY25)

Therapeutics	Diagnostics	Academic and Government	Industry and applied	Global supply partners
+49%	+15%	+32%	-6%	-1%
$40.4M	**$43.8M**	**$15.5M**	**$5.7M**	**$12.9M**
Discovery research Including AI-enabled Drug Discovery	Tools for NGS assays, medical center studies	Research	Chemical and enzyme engineering, agriculture	OEMs and distributors reselling our products

>85% of global supply partner revenue is **NGS Applications**, largely **Diagnostics**

Key Metrics: Revenue, Gross Margin, Adj EBITDA

Annual Revenue
$ in Millions



Quarterly Revenue
$ in Millions



	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY26 Q3
Adjusted R&D and SG&A*	$126M	$164M	$248M	$260M	$253M	$262M	$79.9M
Adjusted EBITDA**	($93.8M)	($106.5M)	($152.8M)	($147.3M)	($93.5M)	($46.9M)	($11.3M)

(unaudited)

*Adjusted R&D and SG&A is defined as SG&A and R&D expenses excluding depreciation and amortization and stock-based compensation expense. See adjusted R&D and SG&A reconciliation beginning on page 27
**Adjusted EBITDA is defined as net income (loss) adjusted to exclude litigation settlement expense, interest income, income tax expense, depreciation and amortization, other income/expense, net, stock-based compensation expense and other items detailed in the reconciliation that we believe are not indicative of our ongoing results. See adjusted EBITDA Reconciliation beginning on page 26

Adjusted EBITDA Progress Toward Break-even in 4Q FY26



Adj. SG&A + Adj. R&D*	$57.4M	$63.3M	$64.4M	$64.1M	$60.7M	$64.6M	$67.4M	$65.5M	$64.5M	$73.1M	$76.7M	$79.9M
Adj EBITDA:**	($26.4M)	($27.8M)	($26.8M)	($22.0M)	($17.0M)	($16.3M)	($14.8M)	($8.0M)	($7.8M)	($13.4M)	($13.3M)	($11.3M) (unaudited)

See page 29 for Adjusted SG&A and Adjusted R&D reconciliation.
** *See page 28 for ADJ. EBITDA reconciliation*

FY2026 Guidance*

Q4 FY2026	FY2026	FY2026
REVENUE	REVENUE	GROSS MARGIN
$123 to $124M	**$456 to $457M**	**>52%**
Growth of 25% YoY at midpoint	Growth of 21% YoY	

Adjusted EBITDA Breakeven Expected for Q4 FY2026**

* Guidance provided as of August 3, 2026

**A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company's future hiring and retention needs, as well as the future fair market value of its common stock, all of which are difficult to predict and are subject to change. The actual amount of these expenses during fiscal 2026 will have a significant impact on Twist's future GAAP financial result

2030: CONTINUING TO EXPAND SAMS DRIVEN BY NPIs

$6B SAM and >$90B TAM

NGS Applications



Sources: DeciBio, FactMR, Evercore ISI, Guggenheim Securities, Canaccord Genuity, Twist internal estimates

$7B+ SAM* and $18B TAM

DNA Synthesis and Protein Solutions



Sources: Fortune Business Insights, Market and Markets, Roots Analysis, Grand View, GMI, Nova1 Advisors, Verified Market Research, Data Insights Market, Leerink, Data Intelligence, Prescedence Research, Verified Market Reports, Twist internal estimates

One Platform, Many Customized Solutions

Meeting customers where they are, powering growth across expanding platforms

How we win

- Operational excellence
- NPI machine
- Commercial execution

TWIST BIOSCIENCE

Differentiated Silicon Platform Speed and Scale

Twist products are for research use only. The products presented here are not intended for the diagnosis, prevention, or treatment of a disease or condition. Twist Bioscience assumes no liability regarding use of the product for applications in which it is not intended. The results are specific to the institution to which they were obtained. The results presented are customer-specific and should not be interpreted as indicative of performance across all institutions.

AI-enabled antibody discovery workflow
AI-ready wet-lab at scale

Molecular residual disease
Personalized diagnostic research at scale

Enzyme-engineered NGS
Better performance, integrated workflow

Nucleic acid therapeutics
Next growth frontier

Twist culture

Executing with Increasing Visibility, Delivering Durable Growth

Revenue Growth

23% YoY growth for 14th quarter of consecutive growth

Strong Growth Trajectory

More than double revenue from organic revenue in 2031

Guided $123 to $124M in 4Q FY26

Growth of approximately 25% year over year

Triple Digit % Order Growth for AI-enabled DD

Meet or exceed AI enabled drug discovery for FY26 vs FY25

Repeat Triple Digit % Order Growth for AI-enabled DD

Based on robust funnel for AI enabled drug discovery for FY27

>52% Gross Margin for FY26

Line of sight to 60%+ gross margin as business matures

Adjusted EBITDA breakeven

in 4QFY26

Customers

Remain at the center of all we do daily

TWIST BIOSCIENCE

Writing the Future

Adjusted EBITDA Reconciliation

(In Thousands)	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY2025
GAAP Net Income (Loss)	**($139,931)**	**($152,098)**	**($217,863)**	**($204,618)**	**$(208,726)**	**$(77,670)**
Add (Deduct) Adjustments:						
Interest income	(1,499)	(435)	(3,062)	(14,365)	(15,344)	(11,364)
Interest expense	787	367	80	—	—	—
Income tax expense (benefit)	382	(1,930)	(10,411)	1,152	560	719
Depreciation and amortization	6,677	9,750	16,514	29,310	31,432	24,853
EBITDA	**($133,584)**	**($144,346)**	**($214,742)**	**($188,521)**	**$(192,079)**	**$(63,462)**
Add (Deduct) Adjustments:						
Other income/expense, net	182	1,370	1,087	672	2,679	903
Stock-based compensation expense	17,096	36,998	79,664	30,278	50,925	64,459
Gain on sale of business	—	—	—	—	—	(48,847)
Gain on deconsolidation of business	—	—	(4,607)	—	—	—
Litigation settlement	22,500	—	—	—	—	—
Change in fair value of contingent considerations and holdbacks	—	(534)	(14,245)	(5,912)	—	—
Restructuring costs	—	—	—	9,384	—	—
Impairment of long-lived assets	—	—	—	6,785	44,930	—
Adjusted EBITDA	**($ 93,806)**	**($106,512)**	**($152,843)**	**($147,314)**	**$(93,545)**	**$(46,947)**

Adjusted R&D and SG&A Expenses Reconciliation

(In Millions)	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
R&D Expenses — GAAP	**$43.0**	**$69.1**	**$120.3**	**$106.9**	**$90.9**	**$80.3**
Adjusted to exclude:						
Depreciation and Amortization	3.0	3.2	3.5	4.0	3.0	1.3
Stock-based Compensation Expense	3.3	10.2	19.5	13.9	11.2	9.0
Adjusted R&D Expenses	**$36.7**	**$55.7**	**$97.3**	**$88.9**	**$76.6**	**$70.0**
SG&A Expenses — GAAP	**$103.3**	**$135.9**	**$212.9**	**$189.7**	**$218.4**	**$247.0**
Adjusted to exclude:						
Depreciation and Amortization	1.8	3.6	6.5	6.9	6.8	6.5
Stock-based Compensation Expense	12.5	24.2	55.5	11.8	35.7	48.5
Adjusted SG&A Expenses	**$89.0**	**$108.2**	**$150.9**	**$171.1**	**$175.9**	**$192.0**
Adjusted R&D and SG&A Expenses	**$125.7**	**$163.9**	**$248.2**	**$260.0**	**$252.5**	**$262.0**

Adjusted EBITDA Reconciliation

(In Thousands)	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
GAAP Net Income (Loss)	**($46,243)**	**($43,008)**	**($45,492)**	**($85,571)**	**($34,655)**	**($31,594)**	**($39,328)**	**$20,390**	**($27,138)**	**($30,507)**	**($44,021)**	**($35,051)**
Add (Deduct) Adjustments:												
Interest Income	(3,893)	(4,120)	(3,941)	(3,663)	(3,620)	(3,240)	(2,801)	(2,690)	(2,633)	(2,175)	(1,710)	(1,500)
Income Tax Expense	(221)	120	345	191	(96)	97	175	191	256	253	43	311
Depreciation and Amortization	8,500	8,171	8,304	8,301	6,656	6,382	6,402	6,065	6,004	6,194	6,414	6,778
EBITDA	**($41,857)**	**($38,837)**	**($40,784)**	**($80,742)**	**($31,715)**	**($28,355)**	**($35,552)**	**$23,956**	**($23,511)**	**($26,235)**	**($39,274)**	**($29,462)**
Add (Deduct) Adjustments:												
Other Income/Expense, Net	246	31	199	121	2,327	93	394	836	(420)	(471)	(175)	(40)
Stock-based Compensation Expense	11,747	11,020	13,824	13,734	12,347	11,991	20,328	16,057	16,083	13,273	18,936	18,176
Litigation settlement costs, net of recoveries	—	—	—	—	—	—	—	—	—	—	7,205	—
Gain on sale of business	—	—	—	—	—	—	—	(48,847)	—	—	—	—
Restructuring and other costs	332	—	—	—	—	—	—	—	—	—	—	—
Impairment of long-lived assets	3,165	—	—	44,930	—	—	—	—	—	—	—	—
Adjusted EBITDA	**($26,367)**	**($27,786)**	**($26,761)**	**($21,957)**	**($17,042)**	**($16,271)**	**($14,830)**	**($7,998)**	**($7,848)**	**($13,433)**	**($13,307)**	**($11,326)**

Adjusted R&D and SG&A Expenses Reconciliation

(In Millions)	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
R&D Expenses — GAAP	**$23.7**	**$23.1**	**$24.1**	**$22.5**	**$21.1**	**$21.3**	**$23.9**	**$18.0**	**$17.0**	**$17.1**	**$19.7**	**$18.0**
Adjusted to exclude:												
Depreciation and Amortization	0.8	0.9	0.9	0.9	0.5	0.4	0.4	0.2	0.2	0.2	0.2	0.3
Stock-based Compensation Expense	3.1	2.8	3.4	2.4	2.6	2.7	3.5	0.9	1.8	1.6	2.1	1.7
Adjusted R&D Expenses	**$19.9**	**$19.4**	**$19.9**	**$19.2**	**$18.1**	**$18.1**	**$20.0**	**$16.9**	**$15.0**	**$15.3**	**$17.4**	**$16.0**
SG&A Expenses — GAAP	**$47.4**	**$52.8**	**$55.6**	**$56.8**	**$53.1**	**$56.2**	**$63.7**	**$63.4**	**$63.8**	**$69.7**	**$76.1**	**$80.7**
Adjusted to exclude:												
Depreciation and Amortization	1.9	1.7	1.7	1.6	1.8	1.6	1.6	1.7	1.6	1.6	1.7	1.8
Stock-based Compensation Expense	8.0	7.3	9.4	10.3	8.8	8.0	14.7	13.1	12.7	10.4	15.1	15.0
Adjusted SG&A Expenses	**$37.5**	**$43.9**	**$44.5**	**$44.9**	**$42.6**	**$46.5**	**$47.4**	**$48.6**	**$49.5**	**$57.8**	**$59.3**	**$63.9**
Adjusted R&D and SG&A Expenses	**$57.4**	**$63.3**	**$64.4**	**$64.1**	**$60.7**	**$64.6**	**$67.4**	**$65.5**	**$64.5**	**$73.1**	**$76.7**	**$79.9**